EVOLUS, INC. Interest Expense
EVOLUS, INC. (EOLS) reported Interest Expense of $4.70 million for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-07.
Discontinued › Expense Statement
us-gaap:InterestExpense · last filed 2024-05-07
- EVOLUS, INC. interest expense for the quarter ending 2024-03-31 was $4.70M, a 68.59% increase year-over-year.
- EVOLUS, INC. interest expense for the quarter ending 2023-12-31 was $4.08M, a 54.88% increase year-over-year.
- EVOLUS, INC. interest expense for the quarter ending 2023-09-30 was $3.79M, a 61.59% increase year-over-year.
- EVOLUS, INC. interest expense for the quarter ending 2023-06-30 was $3.18M, a 53.35% increase year-over-year.
- EVOLUS, INC. interest expense for fiscal 2023 was $13.83M, a 52.05% increase from fiscal 2022.
- EVOLUS, INC. interest expense for fiscal 2022 was $9.10M, a 551.65% increase from fiscal 2021.
- EVOLUS, INC. interest expense for fiscal 2021 was $1.40M.
- EVOLUS, INC. interest expense for fiscal 2018 was $863.00K, a 17160.00% increase from fiscal 2017.
| Period end | Interest Expense 3 month | Interest Expense 6 month | Interest Expense 9 month | Interest Expense 12 month |
|---|---|---|---|---|
| 2024-03-31 | $4.70M 10-Q · filed 2024-05-07 | $8.78M derived: sum of 2 quarters · filed 2024-05-07 | $12.56M derived: sum of 3 quarters · filed 2024-05-07 | $15.74M derived: sum of 4 quarters · filed 2024-05-07 |
| 2023-12-31 | $4.08M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07 | $7.86M derived: sum of 2 quarters · filed 2024-03-07 | $11.04M derived: sum of 3 quarters · filed 2024-03-07 | $13.83M 10-K · filed 2024-03-07 |
| 2023-09-30 | $3.79M 10-Q · filed 2023-11-07 | $6.97M derived: sum of 2 quarters · filed 2023-11-07 | $9.76M 10-Q · filed 2023-11-07 | $12.39M derived: sum of 4 quarters · filed 2024-05-07 |
| 2023-06-30 | $3.18M 10-Q · filed 2023-08-02 | $5.97M 10-Q · filed 2023-08-02 | $8.60M derived: sum of 3 quarters · filed 2024-05-07 | $10.95M derived: sum of 4 quarters · filed 2024-05-07 |
| 2023-03-31 | $2.79M 10-Q · filed 2024-05-07 | $5.42M derived: sum of 2 quarters · filed 2024-05-07 | $7.76M derived: sum of 3 quarters · filed 2024-05-07 | $9.84M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $2.63M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07 | $4.97M derived: sum of 2 quarters · filed 2024-03-07 | $7.05M derived: sum of 3 quarters · filed 2024-03-07 | $9.10M 10-K · filed 2024-03-07 |
| 2022-09-30 | $2.34M 10-Q · filed 2023-11-07 | $4.42M derived: sum of 2 quarters · filed 2023-11-07 | $6.47M 10-Q · filed 2023-11-07 | $6.61M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $2.08M 10-Q · filed 2023-08-02 | $4.12M 10-Q · filed 2023-08-02 | $4.26M derived: sum of 3 quarters · filed 2023-08-02 | $4.57M derived: sum of 4 quarters · filed 2023-08-02 |
| 2022-03-31 | $2.05M 10-Q · filed 2023-05-09 | $2.19M derived: sum of 2 quarters · filed 2023-05-09 | $2.50M derived: sum of 3 quarters · filed 2023-05-09 | $2.80M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $140.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-08 | $451.00K derived: sum of 2 quarters · filed 2023-03-08 | $751.00K derived: sum of 3 quarters · filed 2023-03-08 | $1.40M 10-K · filed 2023-03-08 |
| 2021-09-30 | $311.00K 10-Q · filed 2022-11-08 | $611.00K derived: sum of 2 quarters · filed 2022-11-08 | $1.26M 10-Q · filed 2022-11-08 | |
| 2021-06-30 | $300.00K 10-Q · filed 2022-08-02 | $945.00K 10-Q · filed 2022-08-02 | ||
| 2021-03-31 | $645.00K 10-Q · filed 2022-05-10 | |||
| 2018-12-31 | $114.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-20 | $435.00K derived: sum of 2 quarters · filed 2019-03-20 | $756.00K derived: sum of 3 quarters · filed 2019-03-20 | $863.00K 10-K · filed 2019-03-20 |
| 2018-09-30 | $321.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-05 | $642.00K derived: sum of 2 quarters · filed 2018-11-05 | $749.00K 10-Q · filed 2018-11-05 | $754.00K derived: sum of 4 quarters · filed 2019-03-20 |
| 2018-06-30 | $321.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-02 | $428.00K 10-Q · filed 2018-08-02 | $433.00K derived: sum of 3 quarters · filed 2019-03-20 | $433.00K derived: sum of 4 quarters · filed 2019-03-20 |
| 2018-03-31 | $107.00K 10-Q · filed 2018-05-10 | $112.00K derived: sum of 2 quarters · filed 2019-03-20 | $112.00K derived: sum of 3 quarters · filed 2019-03-20 | $112.00K derived: sum of 4 quarters · filed 2019-03-20 |
| 2017-12-31 | $5.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-20 | $5.00K derived: sum of 2 quarters · filed 2019-03-20 | $5.00K derived: sum of 3 quarters · filed 2019-03-20 | $5.00K 10-K · filed 2019-03-20 |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-05 | $0.00 derived: sum of 2 quarters · filed 2018-11-05 | $0.00 10-Q · filed 2018-11-05 | |
| 2017-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-02 | $0.00 10-Q · filed 2018-08-02 | ||
| 2017-03-31 | $0.00 10-Q · filed 2018-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |